TokenPost·
PharmaCyte Biotech Board Approves 1-for-19 Reverse Stock Split
The split is intended to help the company meet Nasdaq's minimum bid price requirement for continued listing. Split-adjusted trading is scheduled to begin Nov. 13.
More news
- TokenPostHyperliquid Asks nanoreth Operators to Update for hl-node Compatibility
- TokenPostDeutsche Bank Opens Bitcoin Custody to European Institutions
- TokenPostJ.P. Morgan Analyst Upgrades Mercury Systems to Overweight
- TokenPostCoinbase Adds New Auto-stop Controls for AI Agent Trades
- TokenPost@solana Says Most Traditional Financial Assets Could Move On-Chain in Five to 10 Years
- Crypto BriefingBlackRock’s IBIT sees $269.7 million in outflows as Bitcoin ETF exodus continues